iGEM parts and patents

Written byAlla Katsnelson

| 2 min read

This year's iGEM linkurl:winners;http://www.the-scientist.com/blog/display/53832/ tackled a rather abstract information processing task, but many of the projects had direct health applications. In addition to the bactoblood and HIV project, there was a heart stem cell project, non-antibiotic resistant bacteria, a detection system for infections, and more. I asked Jeff Way of Merck KGaA in Germany, who was at the Jamboree as a judge, whether pharma and biotech companies were starting to apply synthetic biology approaches to drug development. Way (who cowrote an linkurl:article;http://www.the-scientist.com/article/display/14950/ on synthetic biology for The Scientist) said that with the first wave of innovative biotech products going off-patent, industry sorely needs some new ideas, but he didn't think the jump into synthetic biology was on the immediate horizon. "The design principles here have huge potential, but it's not really being realized," he said, in part because the mentality is still largely dominated by chemical synthesis of fairly simple molecules. A new mindset, he said, will have to come from a wave of new companies and a younger generation of biological engineers. Leonard Katz, the research director of the linkurl:Synthetic Biology Engineering Research Center;http://www.synberc.org/index.html (SynBERC), a multi-institutional NISF-funded effort to develop the field of synthetic biology, said that one of SynBERC?s immediate missions is to reach out to industry and to promote the field's potential both for the discovery of novel drugs and production methods. But with synthetic biology's stress on an open-source Registry of Biological Parts, what about the intellectual property issues? The Berkeley group's presentation on bactoblood was the only one I saw that raised the question directly. In addition to the requisite biology and engineering students on the team, one member was an anthropology major, who was tasked with researching how the invention could be patented. The answer is, it's unclear. During the question and answer session, MIT's Drew Endy asked the team, how do you build a patented device from open source parts? "They didn't have an answer for that," he said later. "My answer is, you can't." But inventions that are commercially important will be patented, Way said. "If you want to go over to the dark side, you have to live with the restrictions." He predicts a two-track system, in which companies would simply have to synthesize their own cellular parts. With the cost of synthesis so low, this would barely make a dent in company budgets, he noted. Indeed, that divide is already happening within privately funded projects in academia, pointed out Berkeley's Adam Arkin (and bactoblood's faculty advisor). For example, the University of California recently received more than $600 million in funding from BP and the Department of Energy for bioenergy research, which will certainly involve synthetic biology. But the funders retain some IP rights, so researchers working on those projects simply won't be able to use biobrick parts, Arkin said. I expect many of these ideas will be discussed in the next two days as the meeting turns to workshops; a session on legal standards is slated for Tuesday. I'll have to learn about it later, though, since I've returned to Philadelphia.

iGEM parts and patents

The Scientist ARCHIVES

Become a Member of

Meet the Author

Alla Katsnelson

Related Research Resources

A Stubborn Gene, a Failed Experiment, and a New Path

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies